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Multiple-micronutrient supplementation in pregnant
adolescents in low- and middle-income countries: a systematic
review and a meta-analysis of individual participant data
Emily C. Keats, Nadia Akseer, Pravheen Thurairajah, Simon Cousens, Zulfiqar A Bhutta the Global
Young Women’s Nutrition Investigators’ Group1
Context: Approximately 7.3 million births occur annually among adolescents in
low- and middle-income countries. Pregnant adolescents constitute a nutritionally
vulnerable group that could benefit from intervention to mitigate the mortality and
adverse birth outcomes associated with adolescent pregnancy. Objective: The
aim of this systematic review and meta-analysis was to assess the following: (1)
the effect of multiple-micronutrient (MMN) supplementation vs iron and folic acid
(IFA) supplementation among adolescents on maternal morbidity, birth outcomes,
and mortality outcomes, (2) the effects of MMN supplementation in adolescents
compared with the effects in adult women, and (3) the effect modification, if any,
of MMN supplementation by baseline and geographic characteristics of adoles-
cents. Data Sources: MEDLINE and Cochrane databases were searched, along
with the reference lists of relevant reviews. Study Selection: Multiple-micronutrient
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supplementation trials in pregnancy that were conducted in a low- or middle-
income country and had included at least 100 adolescents (10–19 years of age)
were eligible for inclusion. Two independent reviewers assessed study eligibility.
Data Extraction: Thirteen randomized controlled trials conducted in Africa and
Asia were identified from 1792 reviews and 1578 original trials. Individual-level
data was shared by study collaborators and was checked for completeness and ex-
treme values. One- and two-stage individual participant data meta-analyses were
conducted using data from randomized controlled trials of MMN supplementation.
Results : A total of 15 283 adolescents and 44 499 adult women with singleton
births were included in the individual participant data meta-analyses of MMN sup-
plementation vs IFA supplementation. In adolescents, MMN supplementation re-
duced low birth weight (1-stage OR¼ 0.87, 95%CI 0.77–0.97; 2-stage OR¼ 0.81;
95%CI 0.74–0.88), preterm birth (1-stage OR¼ 0.88, 95%CI 0.80–0.98; 2-stage
OR¼ 0.86, 95%CI 0.79–0.95), and small-for-gestational-age births (1-stage
OR¼ 0.90, 95%CI 0.81–1.00; 2-stage OR¼ 0.86, 95%CI 0.79–0.95) when compared
with IFA supplementation. The effects of MMN supplementation did not differ be-
tween adolescents and older women, although a potentially greater reduction in
small-for-gestational-age births was observed among adolescents. Effect modifica-
tion by baseline characteristics and geographic region was inconclusive.
Conclusions : Multiple-micronutrient supplementation can improve birth outcomes
among pregnant adolescents in low- and middle-income countries. Policy related
to antenatal care in these settings should prioritize MMN supplementation over the
currently recommended IFA supplementation for all pregnant women, especially
adolescents.
INTRODUCTION
Global research and programming priorities in the era
of the United Nations (UN) Sustainable Development
Goals, established in 2015, have begun to encompass
population groups that, up to now, have been left be-
hind. Today, there are 1.2 billion adolescents aged 10 to
19 years who constitute 16% of the world’s population,1
and 9 of 10 live in a low- or middle-income country
(LMIC).2 Within this cohort are 600 million adolescent
women (18–19 years) and girls (<18 years)2 whose
health and well-being is critical for sustainable
development.3
The nutrition of adolescent girls and adolescent
women in LMICs is especially important because of the
high burden and severe consequences of malnutrition
(encompassing underweight, overweight/obesity, and
micronutrient deficiencies) in these settings.4
Malnutrition can manifest in several different ways,
leading to infections, noncommunicable diseases, dis-
ability, or death. Pregnant adolescents are particularly
at risk because of the heightened nutritional demands
imposed by the fetus coupled with those required for
growth during adolescence, with inadequate nutrition
having intergenerational consequences for the
offspring.5 Compared with older women, adolescents
are at higher risk of adverse pregnancy outcomes, in-
cluding maternal morbidities (eg, eclampsia and
obstructed labor), stillbirth, preterm birth, and severe
neonatal conditions.6,7 In addition, complications of
pregnancy are the leading cause of death for girls and
women aged 15 to 19 years in LMICs.8 Underlying mi-
cronutrient deficiencies are prevalent in LMICs, where
diet diversity is lacking, and may exacerbate some of
these outcomes and negatively impact the growth and
development of the infant.6,9 Additionally, multiple
pregnancies and short interpregnancy intervals can
contribute to poor micronutrient status for mothers of
any age.10 Given the large number of adolescent girls
who will soon enter their reproductive years, the 7.3
million births to adolescents in LMICs per year,11 and
the importance of good nutrition prenatally and
throughout pregnancy, interventions to alleviate this
burden of malnutrition will be essential if the
Sustainable Development Goals, particularly
Sustainable Development Goal 3, are to be achieved.
Currently, the World Health Organization (WHO)
recommends daily supplementation with iron and folic
acid (IFA) throughout pregnancy,12 but recent evidence
indicates that a multiple-micronutrient (MMN)
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supplement provides additional benefits to IFA supple-
mentation and has the advantage of addressing multiple
deficiencies simultaneously. A 2019 Cochrane review of
19 randomized controlled trials in LMICs found that
supplementation with MMN, when compared with IFA
supplementation, can reduce the risk of low birth
weight (LBW) and small-for-gestational age (SGA)
newborns and may reduce preterm births among
women of reproductive age generally.13 However, this
review did not examine outcomes in adolescents, and
the extent to which MMN supplementation benefits
pregnant adolescents has received relatively little atten-
tion overall, underscoring an important gap in knowl-
edge for evidence-based programming and policy.
Given the current gap, both a one-stage individual
participant data (IPD) meta-analysis and a two-stage
IPD meta-analysis were conducted to investigate the ef-
fect of MMN supplementation in pregnant adolescent
girls and women and to identify risk factors relating to
the health, survival, and nutritional status of these girls
and women and their offspring. Specifically, 3 objec-
tives were addressed: (1) the effect of MMN vs IFA sup-
plementation in pregnant adolescent girls and women;
(2) the intervention effect in adolescents compared with
that in adult women of reproductive age; and (3) the
potential variations in the intervention effect in adoles-
cents by individual-level characteristics and region.
METHODS
Mapping of available nutrition-specific intervention
data
To identify studies for inclusion in this analysis, a sys-
tematic review of systematic reviews and meta-analyses
published in 2010 or later was undertaken. Eligible
reviews investigated effects of nutrition-specific inter-
ventions provided to women of reproductive age in
LMICs. This date criterion was applied to the search in
order to capture recent data relevant to the research
questions. The PICOS (Participants, Intervention,
Comparison, Outcome, Study design) criteria were
used to translate the research question into a searchable
query (Table 1). Searches were conducted in MEDLINE
(see Appendix S1 in the Supporting Information online)
and the Cochrane Library (adapted MEDLINE search)
in September 2016, and the search was updated in
March 2020. Studies from relevant systematic reviews
(ie, those that met the inclusion criteria) were then
assessed by two independent reviewers, and eligibility
criteria (see Table S1 in the Supporting Information on-
line) were applied. Reference lists of included reviews
and grey literature were also searched. Only individu-
ally randomized or cluster-randomized controlled trials
were considered for inclusion, and the analysis was re-
stricted to trials that had enrolled at least 100 healthy
adolescent girls or women (10–19.9 years). An excep-
tion to this was the inclusion of the study by Adu-
Afarwuah et al14 (N¼ 71 adolescents) because of the
limited availability of lipid-based nutrient supplementa-
tion trials. When necessary, trial investigators were con-
tacted for clarification (eg, to determine sample size of
adolescents). Risk-of-bias assessment was completed for
each trial using the Cochrane risk-of-bias tool, and the
results are reported in Appendix S2 in the Supporting
Information online. PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses)
guidelines for reporting of systematic reviews were fol-
lowed; the corresponding checklist can be found in
Appendix S3 in the Supporting Information online.
Formation of the Global Young Women’s Nutrition
Investigators’ Group
Investigators of trials that met the inclusion criteria
were invited to join the Global Young Women’s
Nutrition Investigators’ Group. A complete listing of
the Investigators’ Group, which includes 35 members,
can be found in Table S2 in the Supporting Information
online. For trials that provided supplementation in
pregnancy with MMN vs IFA or with lipid-based nutri-
ent supplements (LNS) vs IFA, IPD were requested.
Given that LNS contains multiple micronutrients, a pre-
specified sensitivity analysis was conducted in which
outcomes were reexamined when data from MMN and
LNS trials were combined (MMN þ LNS vs IFA).
Outcomes and covariates of interest
All outcomes, potential individual-level effect modifiers,
and statistical methods were specified a priori. The out-
comes were birth weight, LBW (<2500 g), gestational
age, preterm birth (<37 weeks of gestation), SGA birth
(<10th centile, based on INTERGROWTH-21st stand-
ards15), stillbirth (fetal death 28 weeks of gestation),
perinatal mortality (fetal deaths 28 weeks of gestation
up to day 7 of life), neonatal mortality (death up to day
28 of life), maternal hemoglobin level, and maternal
anemia (third trimester hemoglobin <11 g/dL). The
covariates were age at enrollment (<20 years vs
20 years and <18 years vs 18–19 years), region (Africa
vs Asia), parity (primiparous vs multiparous), body
mass index (BMI) (underweight [BMI <18.5] vs not
underweight [BMI 18.5]), gestational age at enroll-
ment (<13 weeks vs 13 weeks), maternal height (low
stature [<150 cm] vs normal stature [150 cm]), mater-
nal education (none vs some), and maternal anemia
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status at enrollment (anemic [hemoglobin <11 g/dL] vs
nonanemic [hemoglobin 11 g/dL]).
Because parity could modify the effects of age, the
potential age effect (<18 years vs 18–19 years) among
primiparous adolescents was also investigated.
Investigators provided data sets based on these specifi-
cations. Data sets received were assessed to ensure con-
sistency with published reports, and implausible values
were excluded (see Table S3 in the Supporting
Information online).
Statistical analysis
While IPD meta-analyses are now considered the gold
standard of evidence syntheses, a one-stage approach in
which all IPD are analyzed simultaneously in one re-
gression model can have both advantages and disadvan-
tages over a two-stage approach in which aggregate
estimates are derived separately for each study and then
combined in a fashion similar to a traditional meta-
analysis.16 There remains some debate surrounding
which statistical approach should be adopted in a given
situation. Consequently, both a one-stage IPD meta-
analysis (primary analysis) and a two-stage IPD meta-
analysis were performed, using data from primary trials
that were analyzed on an intention-to-treat basis. All
multiple births were excluded. Stata software version 15
(StataCorp) was used to conduct all analyses.
Following examination of the age distribution of
adolescent girls and women in the trials available, anal-
yses by age within this population focused on the com-
parison of girls aged less than 18 years with women
aged 18 to 19.9 years. Too few girls were aged less than
18 years to allow further subdivision within this group.
One-stage IPD meta-analysis
The one-stage IPD approach fits a single model to all of
the participant-level data simultaneously. For continu-
ous outcomes, linear regression models were used.
Results are presented as mean differences (MDs), with
95% confidence limits, between control and
intervention groups. For binary outcomes, logistic re-
gression was used. The logistic regression models pro-
duced odds ratios (ORs) with 95% confidence limits.
With respect to the first and second study objectives,
models were fitted that included an interaction term be-
tween age and intervention, which allowed age-specific
effect estimates to be calculated and a test for effect
modification to be performed. For the third objective,
the analysis was restricted to women younger than
20 years of age, and again, interactions were included in
the models. Potential effect modifiers are listed above
(section Outcomes and covariates of interest) as covari-
ates of interest. All models included maternal age and
study as fixed effects, since both of these variables are
predictors of some outcomes and since almost complete
data (ie, few missing observations) were available for
these variables.
Because of the presence of cluster-randomized tri-
als within the data set, a random-effects model was used
to account for between-cluster variation. However, for
binary outcomes, fitting models that allowed for differ-
ing magnitudes of between-cluster variance in different
trials led to convergence problems. Therefore, a con-
stant between-cluster variance was assumed across the
cluster-randomized trials. For continuous outcomes,
results reported allow for differing between-cluster vari-
ation across trials whenever possible (ie, when models
converged).
Inclusion of a random effect for treatment was pre-
ferred in order to allow for between-study variation in
intervention effects, given likely differences in the mi-
cronutrient status of women in different trials.
However, having between-cluster random effects along
with a random effect for treatment caused convergence
issues for many models. Where this occurred, fixed
effects for treatment were used.
Two-stage IPD meta-analysis
A two-stage IPD analysis was also performed. Summary
parameter estimates were calculated for each study.
Estimated parameters included both “main effects”
Table 1 PICOS criteria for inclusion of studies
Parameter Description
Population Women of reproductive age, including adolescents (10–19.9
years of age)
Intervention Multiple-micronutrient supplementation or lipid-based nutrient
supplementation
Comparison Iron and folic acid supplementation
Outcomes Birth weight, low birth weight, gestational age, preterm birth,
small-for-gestational age birth, stillbirth, perinatal mortality,
neonatal mortality, maternal hemoglobin level, maternal
anemia
Study design Individual or cluster-randomized controlled trials
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parameters and interaction parameters. Regression
models, which controlled for maternal age, were fitted
to each study data set using linear regression for contin-
uous outcomes and logistic regression for binary out-
comes. For cluster-randomized trials, random-effects
models were used to account for the cluster randomiza-
tion. Study-specific parameter estimates were displayed
using forest plots and were combined to obtain sum-
mary estimates using the DerSimonian-Laird method.17
This method allows for variation of the treatment effect
between studies, but when there is no between-study
heterogeneity, it will produce the same point estimate
and 95%CI as a fixed-effects analysis. Evidence of effect
modification was assessed by combining study-specific
interaction parameters.
Since IPD from the SUMMIT trial18 were not
obtained, a second prespecified sensitivity analysis was
conducted in which the two-stage IPD results were
compared with a two-stage IPD analysis that included
published aggregate estimates from the SUMMIT trial.
A third sensitivity analysis was conducted post hoc
for selected outcomes in order to test the robustness of
findings once the large Bangladeshi trial19 was removed,
given its oversized contribution to analyses. Two-stage
IPD analyses were conducted with and without inclu-
sion of this trial for birth weight and LBW, SGA birth,
and maternal anemia.
RESULTS
From the mapping exercise, 17 relevant MMN/LNS tri-
als were identified (16 MMN trials, 1 LNS trial), of
which 13 were included in the one- and two-stage IPD
analyses of MMN vs IFA supplementation
(Figure 114,19–30). Three MMN trials were excluded: one
was conducted among nonpregnant women31; one used
a control intervention other than IFA32; and, for the
SUMMIT trial,18 IPD could not be obtained. All other
trials provided IPD. Table 214,19–30 provides a summary
of trials included in the main analysis (MMN vs IFA).
In total, data for 15 283 healthy pregnant adolescents
(10–19 years) and 44 499 healthy older women
(20 years) were available for analysis. Data were ex-
cluded if a woman was HIV positive, had a multiple
pregnancy, had a miscarriage or abortion, or was
assigned to a trial arm other than IFA or MMN supple-
mentation. One large trial conducted in Bangladesh
comprised 48.7% of the total sample (Table 2).19 The
age distribution of women with data available for analy-
sis by trial can be found in Table S4 in the Supporting
Information online. Seven trials provided women with
MMN supplements consistent with the UNIMMAP
(United Nations International Multiple Micronutrient )
composition (30 mg of iron) proposed by the UN and
WHO,33 which contains the recommended dietary al-
lowance of 15 vitamins and minerals, while the remain-
ing 6 trials provided women with adapted UNIMMAP
supplements that contained an iron concentration of
20 mg, 27 mg, or 60 mg per tablet. All MMN tablets also
contained folic acid. Table S5 in the Supporting
Information online summarizes the MMN contents and
dosage by trial. To better understand the prevalence of
the outcomes of interest examined, Table S6 in the
Supporting Information reports outcomes by trial from
the IFA arm.
Figure 214,19–30 and Table 3 present the results of
the one-stage and two-stage IPD meta-analyses for the
following outcomes: LBW, preterm birth, SGA birth,
and maternal anemia in the third trimester.
Figure 314,19–30and Table 3 present results for mortality
outcomes, including stillbirth, perinatal mortality, and
neonatal mortality. When compared with IFA supple-
mentation, MMN supplementation reduced the odds of
LBW (one-stage OR¼ 0.87, 95%CI 0.77–0.97; two-stage
OR¼ 0.81, 95%CI 0.74–0.88) and preterm birth (one-
stage OR¼ 0.88, 95%CI 0.80–0.98; two-stage OR¼ 0.86,
95%CI 0.79–0.95) among adolescents. Using the two-
stage approach, a reduction in SGA births was observed
among adolescents who received MMN supplementa-
tion (OR¼ 0.86, 95%CI 0.79–0.95), while the one-stage
analysis provided weaker evidence of this (OR¼ 0.90,
95%CI 0.81–1.00). For the continuous outcomes
(Table 4), maternal MMN supplementation provided to
adolescents resulted in increased birth weight (one-
stage MD¼ 37 g, 95%CI 15–59; two-stage MD¼ 49 g,
95%CI 33–65). There was also some indication of a
small increase in gestational age (one-stage
MD¼ 0.2 weeks, 95%CI 0.1–0.3; two-stage
MD¼ 0.1 weeks, 95%CI 0.02 to 0.3).
To assess whether the intervention effect differs be-
tween adolescents and adult women of reproductive
age, the test for effect modification by age (<20 years vs
20 years) for each dichotomous outcome (Table 3)
and continuous outcome (Table 4) was reported. Age
did not appear to modify the effect of MMN supple-
mentation for any outcome examined (P for interaction
>0.1 for all outcomes), with the possible exception of
SGA births. There appeared to be a greater positive ef-
fect of MMN supplementation on SGA births for ado-
lescents (two-stage OR¼ 0.86, 95%CI 0.79–0.94) than
for older women of reproductive age (OR¼ 0.97,
95%CI 0.88–1.07; P for interaction¼ 0.05). Results
from the one-stage analysis revealed a similar pattern,
but with weaker evidence of effect modification (P for
interaction¼ 0.18).
To examine whether the intervention effect in ado-
lescents varies by individual-level characteristics, addi-
tional factors that could potentially modify the effect of
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Table 2 Characteristics of studies included in the individual participant data meta-analysis of multiple-micronutrient sup-
plementation vs iron and folic acid supplementation































































27 wk of gestation
per date of last
menstrual period
8468 8018 1297


































12–20 wk of ges-






































5828 3774 309 2017 assigned to
FA only
excluded
Total 83 379 59 782 15 283
Abbreviations: FA, folic acid; IFA, iron and folic acid supplementation; LNS, lipid-based nutrient supplementation; MMN, multiple-micro-
nutrient supplementation.







s/advance-article/doi/10.1093/nutrit/nuab004/6224392 by guest on 15 April 2021
MMN supplementation in adolescent women and girls
were examined (Table 5). There was some evidence to
suggest that maternal BMI and gestational age at enroll-
ment modified the effect of MMN supplementation on
stillbirths among adolescents. The odds of stillbirth
were increased among normal-weight adolescents
(OR¼ 1.26, 95%CI 1.02–1.55) but tended to be reduced
among underweight adolescents (OR¼ 0.79, 95%CI
0.58–1.07; P for interaction¼ 0.01). Additionally, the
odds of stillbirth were increased among those who be-
gan supplementation before 13 weeks of gestation
(OR¼ 1.31, 95%CI 1.06–1.63) but reduced among those
who started supplementation later in pregnancy
(OR¼ 0.75, 95%CI 0.56–0.99; P for inter-
action¼ 0.002). However, given the large number of
statistical tests performed for this analysis, P values
should be interpreted in that light (ie, only a very small
P value among 180 P values would be convincing of an
effect).34
As a sensitivity analysis, a two-stage IPD analysis
that included published aggregate estimates from the
SUMMIT trial18 (for which IPD could not be obtained)
(see Table S7 in the Supporting Information online)
was conducted and compared with a two-stage IPD
without the SUMMIT data (Table 3). For outcomes for
which SUMMIT data were available (LBW, preterm
birth, SGA birth, stillbirth, and neonatal mortality),
there was no important statistical differences between
the two analyses.
As a second sensitivity analysis, outcomes were ex-
amined when data from MMN and LNS trials were
combined (see Table S8 in the Supporting Information
online) using the one-stage approach. This allowed for
the inclusion of one additional trial35 along with LNS
arms from two MMN trials that had not been previ-
ously included.14,20 This strengthened somewhat the ev-
idence that MMN/LNS reduced the risk of SGA birth
(OR¼ 0.88, 95%CI 0.79–0.97) among adolescents.
As a third sensitivity analysis, the outcomes of birth
weight and LBW (see Tables S9 and S10 in the
Supporting Information online), SGA births (see Table
S11 in the Supporting Information online), and mater-
nal anemia (see Table S12 in the Supporting
Information online) were examined after removal of
data from the large Bangladeshi trial.19 This produced
slightly weaker evidence that MMN supplementation
reduced the risk of LBW among adolescents
(OR¼ 0.86, 95%CI 0.72–1.03), though a similar effect
was noted for older women of reproductive age
(OR¼ 0.90, 95%CI 0.80–1.03; P for interaction¼ 0.65).
Evidence of an effect on SGA birth among adolescents
(OR¼ 0.86, 95%CI 0.74–1.00) became slightly more un-
certain, though the point estimate remained the same,
and there was weaker evidence of effect modification by
Table 3 Effect of maternal multiple-micronutrient supplementation containing iron and folic acid compared with iron
and folic acid supplementation alone on low birth weight, preterm birth, SGA birth, stillbirth, neonatal mortality, perina-
tal mortality, and maternal anemia, when stratified by maternal age (< 20 years vs  20 years). Results of one-stage
and two-stage IPD analysis presented
Outcome One-stage IPD analysis Two-stage IPD analysis
No. of trials OR (95%CI) Test for
interaction




All women 13 0.87 (0.80–0.95)a 13 0.86 (0.79–0.92)a
Age <20 y 0.87 (0.77–0.97)a P¼ 0.89 0.81 (0.74–0.88)a P¼ 0.65
Age 20 y 0.87 (0.80–0.95)a 0.88 (0.79–0.99)a
Preterm birth (<37 wk) All women 13 0.89 (0.83–0.95)a 13 0.87 (0.83–0.92)a
Age <20 y 0.88 (0.80–0.98)a P¼ 0.87 0.86 (0.79–0.95)a P¼ 0.67
Age 20 y 0.89 (0.83–0.96)a 0.88 (0.82–0.95)a
SGA birth (<10th centile) All women 13 0.95 (0.87–1.03) 13 0.94 (0.87–1.01)
Age <20 y 0.90 (0.81–1.00)a P¼ 0.18 0.86 (0.79–0.94)a P¼ 0.05a
Age 20 y 0.96 (0.88–1.04) 0.97 (0.88–1.07)
Stillbirth (28 wk of
gestation)
All women 13 0.96 (0.88–1.05) 13 0.98 (0.86–1.13)
Age <20 y 1.07 (0.90–1.26) P¼ 0.15 1.12 (0.82–1.51) P¼ 0.20
Age 20 y 0.92 (0.83–1.03) 0.95 (0.80–1.12)
Neonatal mortality
(28 d)
All women 10 1.02 (0.93–1.13) 10 1.03 (0.93–1.14)
Age <20 y 0.98 (0.84–1.16) P¼ 0.54 0.99 (0.84–1.16) P¼ 0.83
Age 20 y 1.05 (0.93–1.19) 1.08 (0.88–1.31)
Perinatal mortality
(28 wk of gestation
up to 7 d
All women 11 0.99 (0.92–1.06) 11 1.04 (0.92–1.18)
Age <20 y 1.04 (0.92–1.18) P¼ 0.32 1.07 (0.91–1.25) P¼ 0.28
Age 20 y 0.96 (0.88–1.05) 1.00 (0.84–1.20)
Maternal anemia (Hb in
3rd trimester <110 g/L)
All women 8 1.05 (0.95–1.18) 8 1.06 (0.95–1.19)
Age <20 y 1.07 (0.86–1.33) P¼ 0.94 1.06 (0.86–1.31) P¼ 0.85
Age 20 y 1.06 (0.94–1.18) 1.08 (0.91–1.27)
Abbreviations: Hb, hemoglobin; IPD, individual participant data; OR, odds ratio; SGA, small-for-gestational age.
aStatistically significant estimate.
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age (OR 20 years¼ 0.97, 95%CI 0.86–1.11; P for inter-
action¼ 0.36). However, given the removal of 47%,
47%, and 19% of the total sample for birth weight/LBW,
SGA birth, and maternal anemia, respectively, it was an-
ticipated that estimates would become less precise (ie,
95%CIs became wider for each outcome). No other ma-
jor differences were noted.
DISCUSSION
Multiple-micronutrient supplementation in pregnant
adolescents reduced the odds of LBW, preterm births,
and SGA births. Translating this benefit to a risk ratio,
there was an 8% decline in infants born with LBW and
an 8% decline in preterm births among adolescents who
received MMN supplements compared with current
standard of care (IFA supplements). There was sugges-
tive evidence that MMN benefits adolescents (10–
19 years) more than older women of reproductive age
(20 years) with regard to SGA births, but not other
outcomes. In addition, there was some weak evidence
to suggest that individual-level factors, such as timing of
supplementation initiation and maternal nutritional sta-
tus at baseline, modified the effect of MMN supplemen-
tation on infant survival. Results from the one-stage
and two-stage IPD analyses were generally similar and
led to similar conclusions in terms of impact. For SGA
births among adolescents, a slightly greater effect was
shown with the two-stage IPD analysis, which likely
reflects methodological differences, including model
assumptions, between the two IPD analyses.
Several limitations to this work should be noted.
First, one-stage analyses that include cluster-
randomized trials can lead to computational difficulties,
especially with binary outcomes and when trying to in-
clude random treatment effects. For computations to be
tractable, the between-cluster variance was assumed to
be the same for all cluster-randomized trials. For this
reason, both a one-stage IPD meta-analysis and a two-
stage IPD analysis were conducted. Second, the current
analysis is based on a very large number of statistical
tests (ie, 180 tests were conducted for effect modifica-
tion; Table 5); in this situation, some small P values
should be expected by chance. Specifically, 9 of these
tests would be significant at P< 0.05, by chance.
Considering that fewer than 9 P-for-interaction values
less than 0.05 were reported, it is likely that all of them
are due to chance or can be considered false-positive
results within the analyses. Third, because adolescent
mothers were not specifically recruited for these trials,
the sample of younger adolescents (10–14 years) was
too small to perform meaningful effect modification
within this group or to compare younger adolescents
with older adolescents. Younger adolescents are biologi-
cally different from older adolescents, and some studies
have suggested that pregnancy risks and birth complica-
tions are increased for this group.36,37 Therefore, the
effects of nutrition interventions, including MMN sup-
plementation, could potentially be different within this
subset of mothers. More research is required to deter-
mine this, but it would be practically challenging be-
cause of the need for a large population of pregnant
girls aged 10 to 14 years.
Data on infant sex were not requested, and there-
fore it could not be determined whether there was an
enhanced survival effect for female infants born to ado-
lescent mothers who were supplemented with MMN, as
has been shown for pregnant women of all ages in other
meta-analyses.19,38,39 It has been suggested that this may
be mediated through a longer gestational period and
improved intrauterine growth for female, but not male,
infants.19,38,39 Data from the SUMMIT trial,18 a large
MMN supplementation trial (31 290 women) con-
ducted in Indonesia, are also missing. While the
Table 4 Effect of maternal multiple-micronutrient supplementation containing iron and folic acid compared with iron
and folic acid alone on birth weight (grams), gestational age (weeks), and maternal hemoglobin level (g/dL), when strat-
ified by maternal age (< 20 years vs  20 years). Results of one-stage and two-stage IPD analysis presented
Outcome One-stage IPD analysis Two-stage IPD analysis
No. of
trials








All women 13 þ38 (22–55)a 13 þ40 (27–54)a
Age < 20 y þ37 (15–59)a P¼ 0.89 þ49 (33–65)a P¼ 0.87
Age  20 y þ39 (22–55)a þ36 (16–56)a
Gestational age
(weeks)
All women 13 þ0.2 (0.1–0.3)a 13 þ0.2 (0.1–0.3)a
Age < 20 y þ0.2 (0.1–0.3)a P¼ 0.82 þ0.1 (0.02 to 0.3) P¼ 0.46
Age 20 y þ0.2 (0.1–0.3)a þ0.2 (0.1–0.3)a
Maternal Hb level
(g/dL)
All women 9 0.03 (0.09 to 0.02) 9 0.05 (0.12 to 0.02)
Age < 20 y 0.09 (0.21 to 0.04) P¼ 0.36 0.1 (0.22 to 0.02) P¼ 0.67
Age  20 y 0.02 (0.09 to 0.04) 0.04 (0.12 to 0.05)
Abbreviations: Hb, hemoglobin; IPD, individual participant data; MD, mean difference.
aStatistically significant estimate.
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Table 5 Effect of maternal multiple-micronutrient supplementation on outcomes in adolescent women, stratified by po-
tential effect modifiers (maternal age, region, parity, maternal BMI, gestational age at enrollment, maternal height, ma-
ternal education, and maternal hemoglobin level)
Outcome Characteristic Level OR (95%CI) Test for interaction
Low birth weight (RE) Maternal age <18 y 0.77 (0.68–0.88) P¼ 0.42
18–19 y 0.83 (0.74–0.94)
Maternal age (among primipa-
rous women only)
<18 y 0.75 (0.64–0.86) P¼ 0.38
18–19 y 0.81 (0.71–0.94)
Region Africa 0.87 (0.68–1.10) P¼ 0.55
Asia 0.81 (0.66–0.99)
Parity Primiparous 0.78 (0.70–0.87) P¼ 0.73
Multiparous 0.81 (0.66–1.01)
Maternal BMI <18.5 0.79 (0.67–0.92) P¼ 0.75
18.5 0.81 (0.72–0.91)
GA at enrollment <13 wk 0.81 (0.72–0.90) P¼ 0.95
13 wk 0.81 (0.70–0.94)
Maternal height <150 cm 0.83 (0.73–0.94) P¼ 0.52
150 cm 0.78 (0.69–0.89)
Maternal education None 0.80 (0.66–0.98) P¼ 0.98
Some 0.81 (0.73–0.90)
Maternal Hb <11 g/dL 0.79 (0.59–1.06) P¼ 0.86
11 g/dL 0.82 (0.62–1.10)
Preterm birth (RE) Maternal age <18 y 0.80 (0.69–0.92) P¼ 0.23
18–19 y 0.89 (0.79–1.01)
Maternal age (among primipa-
rous women only)
<18 y 0.80 (0.70–0.93) P¼ 0.17
18–19 y 0.92 (0.80–1.05)
Region Africa 1.00 (0.83–1.21) P¼ 0.10
Asia 0.82 (0.74–0.91)
Parity Primiparous 0.84 (0.76–0.94) P¼ 0.63
Multiparous 0.90 (0.72–1.12)
Maternal BMI <18.5 0.82 (0.69–0.97) P¼ 0.51
18.5 0.87 (0.78–0.97)
GA at enrollment <13 wk 0.84 (0.74–0.95) P¼ 0.51
13 wk 0.89 (0.77–1.03)
Maternal height <150 cm 0.80 (0.69–0.92) P¼ 0.25
150 cm 0.88 (0.78–1.00)
Maternal education None 0.98 (0.81–1.19) P¼ 0.07
Some 0.80 (0.72–0.90)
Maternal Hb <11 g/dL 1.04 (0.82–1.33) P¼ 0.09
11 g/dL 0.76 (0.58–1.01)
SGA birth (RE) Maternal age <18 y 0.78 (0.69–0.89) P¼ 0.05
18–19 y 0.93 (0.83–1.03)
Maternal age (among primipa-
rous women only)
<18 y 0.75 (0.65–0.87) P¼ 0.16
18–19 y 0.86 (0.76–0.98)
Region Africa 0.81 (0.67–0.99) P¼ 0.52
Asia 0.87 (0.80–0.96)
Parity Primiparous 0.81 (0.74–0.90) P¼ 0.09
Multiparous 0.98 (0.80–1.19)
Maternal BMI <18.5 0.95 (0.82–1.11) P¼ 0.15
18.5 0.83 (0.75–0.92)
GA at enrollment <13 wk 0.87 (0.78–0.97) P¼ 0.95
13 wk 0.87 (0.76–0.99)
Maternal height <150 cm 0.93 (0.82–1.05) P¼ 0.13
150 cm 0.82 (0.73–0.92)
Maternal education None 0.85 (0.71–1.03) P¼ 0.96
Some 0.86 (0.78–0.94)
Maternal Hb <11 g/dL 0.81 (0.63–1.03) P¼ 0.23
11 g/dL 0.99 (0.78–1.25)
Stillbirth (FE) Maternal age <18 y 1.14 (0.88–1.47) P¼ 0.54
18–19 y 1.03 (0.82–1.28)
Maternal age (among primipa-
rous women only)
<18 y 1.13 (0.86–1.48) P¼ 0.77
18–19 y 1.07 (0.83–1.38)
Region Africa 1.41 (0.55–3.62) P¼ 0.90
Asia 1.03 (0.86–1.24)
(continued)
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Table 5 Continued
Outcome Characteristic Level OR (95%CI) Test for interaction
Parity Primiparous 1.09 (0.91–1.31) P¼ 0.11
Multiparous 0.72 (0.45–1.17)
Maternal BMI <18.5 0.79 (0.58–1.07) P¼ 0.01a
18.5 1.26 (1.02–1.55)
GA at enrollment <13 wk 1.31 (1.06–1.63) P¼ 0.002a
13 wk 0.75 (0.56–0.99)
Maternal height <150 cm 1.03 (0.82–1.31) P¼ 0.49
150 cm 1.17 (0.91–1.50)
Maternal education None 1.07 (0.75–1.53) P¼ 0.96
Some 1.06 (0.87–1.29)
Maternal Hb <11 g/dL 0.81 (0.48–1.36) P¼ 0.36
11 g/dL 1.15 (0.66–1.98)
Neonatal mortality (FE) Maternal age <18 y 0.95 (0.75–1.20) P¼ 0.69
18–19 y 1.01 (0.82–1.25)
Maternal age (among primipa-
rous women only)
<18 y 0.96 (0.75–1.23) P¼ 0.88
18–19 y 0.99 (0.78–1.25)
Region Africa 1.38 (0.86–2.19) P¼ 0.17
Asia 0.94 (0.79–1.12)
Parity Primiparous 0.98 (0.82–1.16) P¼ 0.99
Multiparous 0.97 (0.60–1.59)
Maternal BMI <18.5 0.97 (0.73–1.27) P¼ 0.92
18.5 0.99 (0.80–1.21)
GA at enrollment <13 wk 0.99 (0.80–1.21) P¼ 0.97
13 wk 0.98 (0.76–1.26)
Maternal height <150 cm 1.01 (0.82–1.26) P¼ 0.59
150 cm 0.93 (0.73–1.18)
Maternal education None 1.12 (0.79–1.61) P¼ 0.43
Some 0.95 (0.79–1.14)
Maternal Hb <11 g/dL 1.39 (0.82–2.34) P¼ 0.82
11 g/dL 1.28 (0.76–2.14)
Perinatal mortality (FE) Maternal age <18 y 1.00 (0.83–1.20) P¼ 0.59
18–19 y 1.07 (0.91–1.26)
Maternal age (among primipa-
rous women only)
<18 y 1.01 (0.83–1.23) P¼ 0.64
18–19 y 1.08 (0.90–1.30)
Region Africa 1.87 (1.05–3.34) P¼ 0.08
Asia 1.01 (0.89–1.16)
Parity Primiparous 1.05 (0.92–1.20) P¼ 0.24
Multiparous 0.83 (0.58–1.19)
Maternal BMI <18.5 0.84 (0.68–1.05) P¼ 0.02
18.5 1.16 (1.00–1.36)
GA at enrollment <13 wk 1.15 (0.98–1.35) P¼ 0.03
13 wk 0.87 (0.71–1.06)
Maternal height <150 cm 1.05 (0.88–1.24) P¼ 0.99
150 cm 1.04 (0.87–1.26)
Maternal education None 1.11 (0.84–1.47) P¼ 0.59
Some 1.02 (0.89–1.17)
Maternal Hb <11 g/dL 1.11 (0.75–1.63) P¼ 0.86
11 g/dL 1.16 (0.77–1.76)
Maternal anemia (RE) Maternal age <18 y 0.82 (0.58–1.18) P¼ 0.08
18–19 y 1.21 (0.93–1.59)
Maternal age (among primipa-
rous women only)
<18 y 0.77 (0.52–1.14) P¼ 0.16
18–19 y 1.09 (0.80–1.49)
Region Africa 0.78 (0.45–1.37) P¼ 0.29
Asia 1.06 (0.89–1.40)
Parity Primiparous 0.98 (0.76–1.25) P¼ 0.09
Multiparous 1.69 (0.94–3.05)
Maternal BMI <18.5 1.16 (0.69–1.96) P¼ 0.65
18.5 1.04 (0.71–1.54)
GA at enrollment <13 wk 1.13 (0.85–1.50) P¼ 0.55
13 wk 0.99 (0.72–1.37)
Maternal height <150 cm 1.09 (0.80–1.48) P¼ 0.90
150 cm 1.06 (0.80–1.41)
Maternal education None 1.05 (0.65–1.68) P¼ 0.86
Some 1.00 (0.79–1.28)
(continued)







s/advance-article/doi/10.1093/nutrit/nuab004/6224392 by guest on 15 April 2021
Table 5 Continued
Outcome Characteristic Level OR (95%CI) Test for interaction
Maternal Hb <11 g/dL 1.01 (0.66–1.54) P¼ 0.74
11 g/dL 0.92 (0.66–1.28)
Birth weight (grams)
(RE)
Maternal age <18 y MD¼57 (32–83) P¼ 0.54
18–19 y MD¼47 (27–68)
Maternal age (among primipa-
rous women only)
<18 y MD¼66 (39–94) P¼ 0.40
18–19 y MD¼51 (27–75)
Region Africa MD¼48.1 (7.7–88.5) P¼ 0.95
Asia MD¼49.2 (31.5–66.8)
Parity Primiparous MD¼57 (39–76) P¼ 0.35
Multiparous MD¼37 (1 to 76)
Maternal BMI <18.5 MD¼50 (21–79) P¼ 0.93
18.5 MD¼51 (32–71)
GA at enrollment <13 wk MD¼54 (33–76) P¼ 0.69
13 wk MD¼48 (23–72)
Maternal height <150 cm MD¼43 (19–68) P¼ 0.46
150 cm MD¼56 (34–77)
Maternal education None MD¼56 (18–93) P¼ 0.81
Some MD¼50 (32–69)
Maternal Hb <11 g/dL MD¼46 (1 to 93) P¼ 0.63
11 g/dL MD¼63 (14–111)
Gestational age (weeks)
(RE)
Maternal age <18 y MD¼0.3 (0.1–0.4) P¼ 0.47
18–19 y MD¼0.2 (0.1–0.3)
Maternal age (among primipa-
rous women only)
<18 y MD¼0.3 (0.1–0.5) P¼ 0.11
18–19 y MD¼0.1 (0.03 to 0.3)
Region Africa MD¼0.15 (0.14 to 0.43) P¼ 1.00
Asia MD¼0.14 (0.07 to 0.34)
Parity Primiparous MD¼0.2 (0.1–0.3) P¼ 0.16
Multiparous MD¼0.4 (0.1–0.7)
Maternal BMI <18.5 MD¼0.3 (0.1–0.5) P¼ 0.60
18.5 MD¼0.2 (0.1–0.4)
GA at enrollment <13 wk MD¼0.3 (0.2–0.4) P¼ 0.15
13 wk MD¼0.1 (0.01 to 0.3)
Maternal height <150 cm MD¼0.3 (0.2–0.5) P¼ 0.13
150 cm MD¼0.2 (0.03–0.3)
Maternal education None MD¼0.1 (0.1 to 0.4) P¼ 0.42
Some MD¼0.3 (0.1–0.4)
Maternal Hb <11 g/dL MD¼0.1 (0.3 to 0.2) P¼ 0.06
11 g/dL MD¼0.3 (0.04–0.6)
Maternal Hb (g/dL) (RE) Maternal age <18 y MD¼0.01 (0.21 to 0.23) P¼ 0.22
18–19 y MD¼0.16 (0.32 to 0.01)
Maternal age (among primipa-
rous women only)
<18 y MD¼0.04 (0.20 to 0.28) P¼ 0.35
18–19 y MD¼0.10 (0.29 to 0.08)
Region Africa MD¼0.25 (1.09 to 0.59) P¼ 0.85
Asia MD¼0.10 (0.22 to 0.03)
Parity Primiparous MD¼0.05 (0.19 to 0.10) P¼ 0.30
Multiparous MD¼0.25 (0.62 to 0.11)
Maternal BMI <18.5 MD¼0.12 (0.37 to 0.14) P¼ 0.89
18.5 MD¼0.10 (0.25 to 0.06)
GA at enrollment <13 wk MD¼0.09 (0.27 to 0.09) P¼ 0.77
13 wk MD¼0.13 (0.32 to 0.07)
Maternal height <150 cm MD¼0.05 (0.14 to 0.24) P¼ 0.03
150 cm MD¼0.23 (0.41 to 0.05)
Maternal education None MD¼0.03 (0.28 to 0.35) P¼ 0.42
Some MD¼0.11 (0.26 to 0.04)
Maternal Hb <11 g/dL MD¼0.17 (0.44 to 0.10) P¼ 0.25
11 g/dL MD¼0.02 (0.17 to 0.21)
Abbreviations: BMI, body mass index; FE, fixed effects; GA, gestational age; Hb, hemoglobin; MD, mean difference; RE, random effects;
SGA, small for gestational age.
aStatistically significant (P< 0.05).
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sensitivity analysis revealed no major differences in ef-
fect when SUMMIT data were included or were not in-
cluded in a traditional meta-analysis, incorporating the
IPD within the one-stage approach would have in-
creased completeness and reduced dependence on the
West et al19 study (JiVitA-3 trial), which contributed al-
most half of the sample to the data set and thus was
weighted heavily in the analyses. Lastly, the important
differences in population characteristics, cointerven-
tions (eg, malaria prophylaxis), and MMN content and
micronutrient dosage within the trial data and their po-
tential effects on the findings should be acknowledged.
However, the aim of this meta-analysis was to deter-
mine the impact of MMN supplementation in adoles-
cent mothers across LMICs, and therefore it is
appropriate as a first-cut technique to pool data that
will maximize sample size and provide a broad indica-
tion of the impact of the intervention.
Compared with other recent evidence syntheses on
this topic, the present analysis shows some similarities
and some differences, which are likely the result of the
differential inclusion and exclusion of studies. In their
analysis of 17 trials (112 953 women) Smith et al38 used
IPD in a two-stage analytic approach to examine poten-
tial individual-level modifiers of the effect of MMN sup-
plementation. Maternal age (<20 years, 20 years) was
one of the potential effect modifiers. These authors also
found no important differences by maternal age for any
of the outcomes examined and noted a greater benefit
of supplementation for women with nutritional defi-
ciency (indicated by low BMI or anemia status). This
analysis demonstrated a trend toward a reduction in
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stillbirth and perinatal mortality outcomes for under-
weight vs normal-weight adolescent women.
The 2019 Cochrane update (N¼ 19 trials; 141 447
women)13 revealed a greater reduction in preterm
births for underweight women, a greater reduction in
Figure 2 Effect of maternal multiple-micronutrient supplementation containing iron and folic acid compared with iron and folic acid supple-
mentation alone on (a) low birth weight, (b) preterm birth, (c) small-for-gestational-age birth, and (d) maternal anemia when stratified by ma-
ternal age (<20 years vs20 years) and using the one-stage and two-stage individual participant data approaches.
Figure 3 Effect of maternal multiple-micronutrient supplementation containing iron and folic acid compared with iron and folic acid supple-
mentation alone on (a) stillbirth, (b) perinatal mortality, and (c) neonatal mortality when stratified by maternal age (<20 years vs 20 years)
and using the one-stage and two-stage individual participant data approaches.
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SGA births for normal-weight and normal-stature
(154.9 cm) women, and greater reductions in SGA
births and perinatal mortality when supplementation
was initiated after 20 weeks of gestation.13 Some benefits
were observed with later initiation of MMN supplemen-
tation (13 weeks of gestation or later compared with
<13 weeks) among adolescent girls and women in this
analysis.
Within the analysis by Smith et al,38 the 2019
Cochrane update,13 and the current analysis, there was
no indication of increased risk of stillbirth, neonatal
mortality, perinatal mortality, or infant/child mortality
with MMN supplementation in pregnancy overall.
However, the tests for effect modification provide some
evidence that stillbirths and perinatal deaths (largely
driven by stillbirths) could be increased among adoles-
cents with BMI 18.5 who receive MMN supplementa-
tion. Similar effects for adolescent mothers who began
supplementation prior to 13 weeks of gestation were
noted, a finding that could be biologically plausible
based on the notion that longer supplementation peri-
ods may lead to larger infants, which could, in turn, in-
crease the risk of birth complications such as asphyxia
and several forms of dysfunctional labor.40,41 However,
given this line of biological reasoning, one might then
assume that the impact among short adolescent moth-
ers would be comparable or even greater, yet stature un-
der 150 cm was not found to increase the risk of
stillbirths with MMN supplementation. In addition,
women with normal BMI vs women with low BMI had
similar outcomes for LBW, preterm birth, SGA birth,
birth weight (grams), and gestational age (weeks).
There is also the potential for imbalanced confounding
(when randomized assignment has not been preserved)
and bias when examining effect modification, as it was
done by conducting a stratified analysis by risk catego-
ries within the smaller subsample of adolescents. Given
the inconsistency of findings for stillbirths compared
with other outcomes and the multiplicity of statistical
tests performed, these results are probably due to
chance and are likely spurious.
Until recently, there has been limited evidence to
support policy and programming initiatives for adoles-
cent mothers in LMICs, despite WHO guidelines on an-
tenatal care for a positive pregnancy experience
encompassing all pregnant women and adolescent
girls.12 For example, no antenatal MMN supplementa-
tion trials focused solely on the adolescent population
have been conducted. An ongoing trial in Pakistan
could help to clarify certain remaining questions. In
this large-scale trial, adolescent and young women (15–
24 years) are provided with a cointervention of life-
skills education and MMN supplements during precon-
ception (twice weekly), pregnancy (daily), and
postpartum (daily to 6 months) or standard of care
(daily IFA and nonregulated, community-based health
sessions) to examine both maternal and infant out-
comes.42 Given the potential nutritional vulnerabilities
of pregnant adolescents, coupled with the high number
of adolescent pregnancies in LMICs, there is a strong
case for targeting pregnant adolescents deliberately to
ensure they receive nutritional supplementation and
quality antenatal and obstetric services. The concurrent
use of targeted strategies for adolescents, such as the use
of promotional platforms (eg, social media, mHealth)6,
could work beneficially to improve the awareness and
uptake of services and, eventually, to improve health
outcomes among adolescent mothers and their infants.
CONCLUSION
The analyses presented here suggest that the impact of
MMN supplementation does not differ substantially be-
tween adolescents and adult women. However, younger
adolescent girls may have different risks related to nu-
trient requirements, nutrient intakes, and health and
birth outcomes when compared with older adolescent
girls and women. While the policy approach should aim
to prevent adolescent pregnancy, further targeted re-
search on the mechanisms of benefit among the youn-
gest mothers would be useful when adolescent
pregnancy does occur. Given these findings, which are
in line with recent efforts to examine the usefulness of
MMN vs IFA supplementation in pregnancy,43 it is rec-
ommend that the global nutrition community support
policy and programming efforts to implement and ex-
pand the use of MMN supplementation, in preference
to IFA supplementation alone, for pregnant women, in-
cluding adolescents in low- and middle-income set-
tings. The cost per MMN tablet is slightly higher than
that of IFA44; however, given the existing channels for
IFA distribution, the additional costs of commodity
change would be minimal while the benefits on birth
outcomes would be potentially greater, especially when
implementation is achieved at scale.44 While current ev-
idence from the subset of MMN trials that report on
long-term health and neurodevelopmental outcomes
does not suggest benefits,45 future studies to capture
such outcomes are warranted. The UN Sustainable
Development Goals will be realized only when the nu-
tritional health and well-being of this critical cohort of
adolescents is optimized.
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